

PERTUSSIS REPORT 22 March–18 April 2025

This fortnightly report summarises pertussis (whooping cough) notifications for the four-week period, 22 March–18 April 2025, and cumulative numbers since the onset of a national pertussis epidemic on 19 October 2024. It includes the distribution of cases by time, region, district, age group and prioritised ethnicity. Four-weekly rates are presented to enable comparisons between groups and over time. This report supplements the Pertussis dashboard which is updated weekly.

Data contained within this report is based on information recorded in EpiSurv as at 11am on 23 April 2025. Changes made to EpiSurv after this time will not be reflected here. Data presented may be further updated and should be regarded as provisional. Cases still under investigation are not included in this report. Because cases that are under investigation are still to be classified, case numbers may change in future reports.

Published 24 April 2025

Summary

- A national pertussis epidemic was declared on 22 November 2024 following an increase in cases throughout New Zealand beginning on 19 October 2024.
- Case numbers and hospitalisations are slightly lower in the four-week period 22 March–18 April 2025 than in the prior four-week period.

In the past four surveillance weeks (weeks 12–15, 22 March–18 April 2025):

- there were 200 cases (119 confirmed and 81 probable) notified in EpiSurv, compared with 238 cases for the prior four weeks (weeks 8–11) This comprises 56, 58, 30 and 56 cases, respectively in weeks 12–15;
- 14 cases were hospitalised, compared with 17 cases in weeks 8–11; no deaths were reported;
- 23 cases (11.5%) were aged less than 1 year, of which five (21.7%) were hospitalised;
- notification rates were highest among infants aged less than 1 year (39.7 per 100,000, 23 cases), followed by children aged 1–4 years (21.7 per 100,000, 53 cases);
- the ethnic group with the highest notification rate was Māori (8.7 per 100,000, 77 cases), followed by Pacific peoples (3.6 per 100,000, 13 cases), and European or Other (3.0 per 100,000, 96 cases);



rates were highest in Te Waipounamu (6.5 per 100,000, 82 cases), followed by Te Manawa Taki (5.3 per 100,000, 56 cases), Central (3.4 per 100,000, 34 cases), and Northern (1.4 per 100,000, 28 cases) regions.

From the beginning of the current national epidemic on 19 October 2024 to 18 April 2025:

- a total of 2282 confirmed, probable and suspect cases of pertussis were notified;
- overall, 191 cases (8.4%) were hospitalised and there has been one death;
- of the 183 cases (8.0%) aged less than 1 year, 89 (48.6%) were hospitalised.

Trends in pertussis cases

A national epidemic was declared on 22 November following a sustained increase in cases throughout New Zealand beginning on 19 October 2024 (Figure 1). Numbers continued to increase in November and December, peaking in early December. Weekly case numbers decreased below this peak in January and February and have decreased further in March and April.

Figure 1. Pertussis cases by week and region, 12 months to 18 April 2025

 $Note: includes \ confirmed, \ probable, \ and \ suspect \ cases \ only. \ Cases \ still \ under \ investigation \ are \ excluded.$



Figure 2 shows monthly pertussis cases since 2010. This shows the current epidemic with case numbers in December equalling or exceeding the highest months seen during the two previous epidemics in 2011–2013, and 2017–2019.

Number of bernassis cases 500 – 100

Figure 2. Pertussis cases by month, January 2010-March 2025

Note: Data for April are not presented as the month is not yet complete.



Trends in pertussis hospitalisations

Pertussis hospitalisations increased in December 2024 and remained high into February, noting there is large week to week variation (Figure 3). In the past four weeks, 14 cases were hospitalised, compared with 17 in the prior four-week period.

Surveillance Week

Figure 3. Pertussis hospitalisations by week, 12 months to 18 April 2025



Cases by age

In the past four weeks, notification rates were highest among infants aged less than 1 year, followed by children aged 1–4 years (Table 1). Infants aged less than 1 year are most vulnerable to severe disease, with a high proportion requiring hospitalisation. Among infants, those aged less than 2 months are at highest risk of severe disease and death.

Table 1. Number and rate of pertussis cases and hospitalisations by age group

	Past 4 weeks			National epidemic to date		
Age Group (years)	22 N	March-18	April 2025	19 October 2024–18 April 2025		
	Cases ¹	Rate ²	Hospitalised	Cases ¹	Hospitalised	
<1	23	39.7	5 (22.7%)	183	89 (49.4%)	
1–4	53	21.7	4 (8.0%)	423	30 (7.4%)	
5–9	31	9.4	0 (0.0%)	364	11 (3.2%)	
10–14	22	6.3	0 (0.0%)	311	9 (3.1%)	
15–19	12	3.5	2 (18.2%)	173	4 (2.5%)	
20–64	52	1.7	2 (4.0%)	725	34 (5.0%)	
65+	5	0.6	1 (20.0%)	101	14 (15.7%)	
Unknown	2	_	0	2	0	
Total	200	3.7	14 (7.4%)	2,282	191 (8.9%)	

¹ Includes confirmed, probable and suspect cases only

² Four week rate of pertussis cases per 100,000 population calculated using 2024 mid-year population estimates from Statistics New Zealand. Rate suppressed if based on fewer than five cases.



Cases by Ethnicity

In the past four weeks, the ethnic group with the highest notification rate was Māori (8.7 per 100,000, 77 cases), followed by Pacific peoples (3.6 per 100,000, 13 cases), and European or Other (3.0 per 100,000, 96 cases) (Table 2).

Hospitalisation rates since 19 October were highest among Māori and Pacific peoples, both overall and for cases <1 year of age.

Further breakdowns of case numbers by age and ethnicity are available on the ESR Pertussis dashboard.

Table 2. Number and rate of pertussis cases by ethnicity

	Past 4 w	eeks	National epidemic to date			
Ethnicity	22 March-18	April 2025	19 October 2024–18 April 2025			
	Cases ¹	Rate ²	Cases ¹	Hospitalised	Cases <1yr	Hospitalised <1yr
Māori	77	8.7	766	94 (12.8%)	115	62 (54.9%)
Pacific peoples	13	3.6	146	29 (20.9%)	14	8 (57.1%)
Asian	8	1.0	81	7 (9.7%)	6	1 (16.7%)
European or Other	96	3.0	1,269	59 (5.0%)	46	17 (37.8%)
Unknown	6	-	20	2	2	1

Note: Ethnicity is prioritised. European and Other includes the MELAA category.

¹ Includes confirmed, probable and suspect cases only

² Four week rate of pertussis cases per 100,000 population calculated using 2024 mid-year population estimates from Statistics New Zealand. Rate suppressed if based on fewer than five cases.



Cases by district

Tairāwhiti District reported the highest rate (16.9 per 100,000) in the last four weeks, followed by Lakes (15.0 per 100,000) (Table 3).

Table 3. Number of pertussis cases, rate and hospitalisations by health district

		Past 4 wee	ks	National epidemic to date		
District	22 N	larch–18 Ap	ril 2025	19 October 2024–18 April 2025		
	Cases ¹	Rate ²	Hospitalised	Cases ¹	Hospitalised	
Northland	6	2.9	1	169	17	
Waitematā	4	-	0	106	17	
Auckland	0	-	0	72	11	
Counties Manukau	18	2.8	2	109	17	
Waikato	7	1.5	2	104	16	
Lakes	18	15.0	2	98	9	
Bay of Plenty	14	5.0	2	180	19	
Tairāwhiti	9	16.9	0	50	3	
Taranaki	8	6.1	2	73	10	
Hawke's Bay	6	3.2	0	142	13	
Whanganui	0	-	0	35	9	
MidCentral	9	4.6	0	113	5	
Hutt Valley	10	6.1	0	82	5	
Capital and Coast	9	2.8	0	159	8	
Wairarapa	0	-	0	30	3	
Nelson Marlborough	8	4.8	0	89	0	
West Coast	0	-	0	45	5	
Canterbury	59	9.4	3	326	15	
South Canterbury	1	-	0	19	4	
Southern	14	3.8	0	281	5	

¹ Includes confirmed, probable and suspect cases only.

² Four week rate of pertussis cases per 100,000 population calculated using 2024 mid-year population estimates from Statistics New Zealand. Rate suppressed if based on fewer than five cases.



Vaccination status of cases aged <12 months

Pertussis vaccination is funded in New Zealand during every pregnancy and as part of the childhood immunisation schedule. The primary series is given at 6 weeks, 3 months and 5 months. Together with the antenatal vaccine, this schedule aims to protect infants against pertussis infection, severe disease requiring hospitalisation, and death.

Table 4 shows the vaccination status of infant pertussis cases notified since the beginning of the national pertussis epidemic and whether they were hospitalised. The majority (90.9%, 80/88) of hospitalised infant cases are either aged <2 months or have not received all of their age-appropriate pertussis vaccine doses.

Information about antenatal vaccination doses for pertussis cases <12 months is not currently available.

Table 4. Vaccination status of cases aged <12 months, by age and hospitalisation, 19 October 2024–18 April 2025

Age Group	Hospi	italised	Not Hospitalised	
<2mths ¹	28 6			
	Not vaccinated for age ²	vaccinated Vaccinated		Vaccinated for age ²
2-3mths	25	6	5	5
4-5mths	9	1	11	0
6-11mths	18	1	38	24

Note: table excludes five cases where vaccination status is unknown and three cases where hospitalisation status is unknown. Source: EpiSurv

Note: Vaccine doses given <14 days prior to date of illness onset are excluded from this analysis as protection is expected to take 14 days to develop.

¹ Vaccination information is not provided for infants <2 months as the first infant dose is offered at 6 weeks and protection takes 14 days to develop.

² A case is considered to be vaccinated for age if they have received at minimum: 1 dose for cases 2 to <4 months; 2 doses for cases 4 to <6 months and 3 doses for cases 6-<12 months.



Appendix – Case definition

Note: The pertussis case definition was revised on 18 December 2024. The suspect case definition was retired as part of this revision.

The case definition in place at the time of preparing this report is provided below. The current case classification used in Aotearoa New Zealand can be found on the <u>Health New Zealand</u> | Te Whatu Ora Communicable Disease Control Manual site.

Clinical criteria

A clinically compatible illness is characterised by a new onset cough without a clear alternative cause and one or more of the following features:

- paroxysms of coughing
- cough ending in vomiting
- inspiratory whoop
- apnoea or cyanosis (in infants aged under 12 months).

Epidemiological criteria

An epidemiological link is established when there is contact between two people at a time when one of them is likely to be infectious AND the other has an illness which starts within 5 to 21 days after this contact AND at least one case in the chain of epidemiologically linked cases (which may involve many cases) has laboratory definitive evidence of pertussis.

Laboratory criteria

Laboratory definitive evidence: Detection of *Bordetella pertussis* nucleic acid by polymerase chain reaction (PCR), OR Isolation of *B. pertussis*

Case classification

- **Confirmed**: a person who has laboratory definitive evidence; OR a person who has a clinically compatible illness AND who has an epidemiological link to a confirmed case.
- Probable: a person who has a clinically compatible illness AND either has a cough lasting 14 days or more OR exposure as part of an outbreak¹
 - ¹an institutional outbreak or community-wide outbreak (when there is limited access to testing)
- **Under investigation**: a person who has been notified, but information is not yet available to classify further.
- **Not a case**: a person who has been investigated and subsequently found not to meet the case definition.